Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Gastroenterology"
DOI: 10.20524/aog.2021.0582
Abstract: Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and… read more here.
Keywords: bowel disease; inflammatory bowel; like illness; disease like ... See more keywords